Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
|Articles|July 1, 2014
(VIDEO) Blastocyst Euploid Selective Transfer (BEST) Trial
Eric J. Forman, MD, FACOG discuses the Blastocyst Euploid Selective Transfer (BEST) Trial carried out by Reproductive Medicine Associates of New Jersey.
Advertisement
Eric J. Forman, MD, FACOG discuses the Blastocyst Euploid Selective Transfer (BEST) Trial carried out by Reproductive Medicine Associates of New Jersey.
Advertisement
Related to this article
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
JoAnn V. Pinkerton, MD, MSCP, on elinzanetant across menopause subpopulations at TMS 2026
3
Brain fog at menopause: Separating normal change from dementia
4
What to expect at The Menopause Society's 2026 Annual Meeting
5